NasdaqGS:CAPRBiotechs
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal
Capricor Therapeutics stock reacts to index removal and regulatory focus
Capricor Therapeutics (CAPR) has come into focus after being removed from several Russell indices, just as investors track upcoming U.S. FDA advisory committee discussions on Deramiocel, its Duchenne muscular dystrophy cell therapy candidate.
See our latest analysis for Capricor Therapeutics.
Capricor Therapeutics shares have come under pressure in the short term, with the stock down 21.82% over seven days and 28.15%...